CataractNCT06891092
Vivinex Impress XY1-EM vs RayOne EMV
A study testing RayOne EMV and Vivinex Impress in people with Cataract, run by Medical University of Bialystok at 1 site in Poland.
Trial summary
Comparison of the outcomes of bilateral implantation of extended depth of vision (EDOF) intraocular lenses (IOLs): the Rayone EMV and the Vivinex Impress XY1-EM in patients with cataract Read more about this study
- Who is it for?
- Ages 21 to 80 years
- Conditions the study is for
- Cataract
- What is being tested?
- RayOne EMV and Vivinex Impress
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 sitePoland
- Study dates
- 1 Jan 2026to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age-related bilateral cataract
- age 21 or older
- visual acuity > 0.05
- axial length: 22.0 - 26.0 mm
- normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- written informed consent prior to surgery
Who cannot join
- active ocular disease (e.g. chronic severe uveitis, proliferative diabetic retinopathy, chronic glaucoma not responsive to medication)
- relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), intraoperative floppy iris syndrome (IFIS)
- corneal decompensation or corneal endothelial cell insufficiency
- previous ocular surgery or trauma
- persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)
- corneal astigmatism > 1 dpt.
- retinopathies
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site, 1 recruiting
- Recruiting
Medical University of Bialystok
Bialystok, Polska, 15-866
Joanna Konopińska, 600471666, joannakonopinska@o2.pl
About this study
Official title: Comparison of Quality of Vision After Implantation of Monofocal Depth-enhanced Intraocular Lenses in Patients Undergoing Bilateral Cataract Surgery
Comparison of the outcomes of bilateral implantation of extended depth of vision (EDOF) intraocular lenses (IOLs): the Rayone EMV and the Vivinex Impress XY1-EM in patients with cataract
Read the detailed description
Cataracts are one of the leading causes of visual impairment and blindness worldwide. Modern cataract surgery by phacoemulsification with intraocular lens implantation is the gold standard of treatment. Conventional monofocal intraocular lenses are still the most commonly used intraocular lenses today. They allow good uncorrected visual acuity to the far distance, while the patient can achieve good visual acuity to the intermediate near distance with glasses.
However, in developed countries, patients expect good quality vision not only to the far distance, but also to intermediate and near distances due to the many daily activities that require this range of vision (reading on tablets and smartphones, driving, carrying on a conversation). To meet these expectations, most intraocular lens manufacturers have introduced extended depth-of-field lens technology, which provides good visual acuity for distance and intermediate distances with few visual side effects. These lenses achieve satisfactory uncorrected visual acuity not only for distance, but also for near and intermediate distances.
Summarising the above arguments, it therefore seems that implanting patients with lenses that allow good distance vision and satisfactory vision to intermediate and near distances can result in an increased quality of life after cataract surgery.
Characteristics of the lenses tested RayOne EMV RAO200E lens (Rayner Intraocular Lenses Ltd) -This lens was developed in collaboration with Professor Graham Barrett. It is a preloaded monofocal+/non-diffractive EDOF, hydrophilic lens that provides an extended range of vision by exploiting positive spherical aberration. The overall diameter of the lens is 12.5mm and the optical diameter is 6.0mm. The lens has an aspherical front surface, biconvex shape. Its effect is to amplify/compensate for the cornea's natural positive spherical aberration, resulting in an increased range of acuity. As it meets ISO standards for monofocal intraocular lenses, it is less affected by variable pupil width, decentration and tilt. The RayOne EMV can be used for bilateral emmetropia and is also optimised for use in a monovision system. For emmetropia, it allows better intermediate vision than standard monovision lenses, providing approximately 1.25 D of extended visual range Vivinex impress XY1-EM (Hoya Surgical Optics, Singapore) - is a new monofocal lens made of hydrophobic non-gloss acrylate with aspheric optics that provides extended depth of field in the intermediate range. It has a combination of standard aspheric and even aspheric surface with microscopic angles. No first studies on the clinical properties of this enhanced monofocal lens are available in the literature.
From the available literature, it appears that both lenses have similar visual improvement efficacy with a similar safety profile. There is currently no study in the available literature directly comparing the two in a randomised manner.
The prospective randomised study will encompass 100 eyes of patients at the Department of Ophthalmology, Medical University of Bialystok, suffering from cataracts in both eyes, qualified for surgical treatment by simultaneous phacoemulsification in both eyes on one day between 2025 and 2028. This method is widely used worldwide. In the local clinic, it was introduced during the Covid-19 pandemic, when hospital visits had to be reduced due to epidemiological risks and the need for social distancing. At present, about 15% of all cataract operations at the clinic here are simultaneous bilateral procedures. Patients who have had no previous ophthalmic surgery and whose health status allows them to participate in the study within 3 months will be eligible. Randomisation will be performed on the day of the patient's qualification for the surgery by means of a draw of the type of lens written on a card placed in a closed envelope.
Group I patients (n=50) will be implanted with Vivinex Impress XY1-EM lenses, group II with RayOne EMV lenses (n=50). Qualification for binaural cataract surgery will be according to NHF guidelines: visual acuity <60% of normal.
Operations will be performed by several, experienced operators. Patients' quality of vision will be assessed 2 times: before surgery and 3 months after surgery using the Visual Function Index Questionnaire (VF 14). The VF-14 is a short questionnaire designed to measure functional motor impairment in cataract patients. It consists of 18 questions covering 14 aspects of visual function of cataract patients. The VF-14 demonstrates high internal consistency and is reliable, providing information that cannot be conveyed by measures of visual acuity or general health. The experiment will be discontinued if the above lenses are found to have an adverse effect on patients' visual quality or biological side effects are identified.
- Conditions
- Cataract
- Being tested
- RayOne EMV, Vivinex Impress
- Keywords
- non-diffractive monofocal IOL, EDOF, cataract
- Medical subject headings
- Cataract
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RayOne EMVDevice
non-diffractive monofocal IOL
Vivinex ImpressDevice
non-diffractive monofocal IOL
| Study group | Role | What they receive |
|---|---|---|
| Rayone EMV | Experimental | Patient will receive the non-diffractive monofocal IOL during cataract surgery Receives: Device: RayOne EMV |
| Vivinex Impress XY1-EM | Experimental | Patient will receive the non-diffractive monofocal IOL during cataract surgery Receives: Device: Vivinex Impress |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual acuity at intermediate distance
The visual acuity at the intermediate distance will be measured using ETDRS charts at a distance of 80 centimetres and compared between the two different IOLs. The higer the number the better outcome.
Measured: 3 months
Secondary outcomes (3)
Visual acuity at far distance
The visual acuity at the far distance will be measured using ETDRS charts at a distance of 4 metres and compared between the two different IOLs. The higer the number the better outcome.
Measured: 3 months
Visual acuity at near distance
The visual acuity at the near distance will be measured using ETDRS charts at a distance of 40 centimetres and compared between the two different IOLs. The higer the number the better outcome.
Measured: 3 months
Change from baseline in the quality of life
Patients' quality of vision will be measured with the Visual Function Index Questionnaire and compared to outcome prior surgery
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2025
- Study start1 Jan 2026
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CataractStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel Assignment
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Bialystok
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06891092
- Sponsor's protocol ID
- 1778
- Status last verified
- Jan 2026
- First submitted
- 17 Mar 2025
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified participant data that underlie the results reported in this study will be available upon reasonable request for academic and non-commercial purposes beginning with results publication and ending 5 years thereafter. Proposals should be submitted to main investigator.
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Quality of Vision After Implantation of Monofocal Depth-enhanced Intraocular Lenses in Patients Undergoing Bilateral Cataract Surgery
- ClinicalTrials.gov ID
- NCT06891092
- Acronym / sponsor ID
- 1778
- Conditions
- Cataract
- Keywords
- non-diffractive monofocal IOL, EDOF, cataract
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Medical University of BialystokUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 24 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Comparison of the outcomes of bilateral implantation of extended depth of vision (EDOF) intraocular lenses (IOLs): the Rayone EMV and the Vivinex Impress XY1-EM in patients with cataract
Detailed description
Cataracts are one of the leading causes of visual impairment and blindness worldwide. Modern cataract surgery by phacoemulsification with intraocular lens implantation is the gold standard of treatment. Conventional monofocal intraocular lenses are still the most commonly used intraocular lenses today. They allow good uncorrected visual acuity to the far distance, while the patient can achieve good visual acuity to the intermediate near distance with glasses.
However, in developed countries, patients expect good quality vision not only to the far distance, but also to intermediate and near distances due to the many daily activities that require this range of vision (reading on tablets and smartphones, driving, carrying on a conversation). To meet these expectations, most intraocular lens manufacturers have introduced extended depth-of-field lens technology, which provides good visual acuity for distance and intermediate distances with few visual side effects. These lenses achieve satisfactory uncorrected visual acuity not only for distance, but also for near and intermediate distances.
Summarising the above arguments, it therefore seems that implanting patients with lenses that allow good distance vision and satisfactory vision to intermediate and near distances can result in an increased quality of life after cataract surgery.
Characteristics of the lenses tested RayOne EMV RAO200E lens (Rayner Intraocular Lenses Ltd) -This lens was developed in collaboration with Professor Graham Barrett. It is a preloaded monofocal+/non-diffractive EDOF, hydrophilic lens that provides an extended range of vision by exploiting positive spherical aberration. The overall diameter of the lens is 12.5mm and the optical diameter is 6.0mm. The lens has an aspherical front surface, biconvex shape. Its effect is to amplify/compensate for the cornea's natural positive spherical aberration, resulting in an increased range of acuity. As it meets ISO standards for monofocal intraocular lenses, it is less affected by variable pupil width, decentration and tilt. The RayOne EMV can be used for bilateral emmetropia and is also optimised for use in a monovision system. For emmetropia, it allows better intermediate vision than standard monovision lenses, providing approximately 1.25 D of extended visual range Vivinex impress XY1-EM (Hoya Surgical Optics, Singapore) - is a new monofocal lens made of hydrophobic non-gloss acrylate with aspheric optics that provides extended depth of field in the intermediate range. It has a combination of standard aspheric and even aspheric surface with microscopic angles. No first studies on the clinical properties of this enhanced monofocal lens are available in the literature.
From the available literature, it appears that both lenses have similar visual improvement efficacy with a similar safety profile. There is currently no study in the available literature directly comparing the two in a randomised manner.
The prospective randomised study will encompass 100 eyes of patients at the Department of Ophthalmology, Medical University of Bialystok, suffering from cataracts in both eyes, qualified for surgical treatment by simultaneous phacoemulsification in both eyes on one day between 2025 and 2028. This method is widely used worldwide. In the local clinic, it was introduced during the Covid-19 pandemic, when hospital visits had to be reduced due to epidemiological risks and the need for social distancing. At present, about 15% of all cataract operations at the clinic here are simultaneous bilateral procedures. Patients who have had no previous ophthalmic surgery and whose health status allows them to participate in the study within 3 months will be eligible. Randomisation will be performed on the day of the patient's qualification for the surgery by means of a draw of the type of lens written on a card placed in a closed envelope.
Group I patients (n=50) will be implanted with Vivinex Impress XY1-EM lenses, group II with RayOne EMV lenses (n=50). Qualification for binaural cataract surgery will be according to NHF guidelines: visual acuity <60% of normal.
Operations will be performed by several, experienced operators. Patients' quality of vision will be assessed 2 times: before surgery and 3 months after surgery using the Visual Function Index Questionnaire (VF 14). The VF-14 is a short questionnaire designed to measure functional motor impairment in cataract patients. It consists of 18 questions covering 14 aspects of visual function of cataract patients. The VF-14 demonstrates high internal consistency and is reliable, providing information that cannot be conveyed by measures of visual acuity or general health. The experiment will be discontinued if the above lenses are found to have an adverse effect on patients' visual quality or biological side effects are identified.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Parallel Assignment
| Arm | Type | Receives |
|---|---|---|
| Rayone EMV | Experimental | Device: RayOne EMVPatient will receive the non-diffractive monofocal IOL during cataract surgery |
| Vivinex Impress XY1-EM | Experimental | Device: Vivinex ImpressPatient will receive the non-diffractive monofocal IOL during cataract surgery |
Who may qualify
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- age-related bilateral cataract
- age 21 or older
- visual acuity > 0.05
- axial length: 22.0 - 26.0 mm
- normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
Key exclusion criteria (7 listed)
- active ocular disease (e.g. chronic severe uveitis, proliferative diabetic retinopathy, chronic glaucoma not responsive to medication)
- relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), intraoperative floppy iris syndrome (IFIS)
- corneal decompensation or corneal endothelial cell insufficiency
- previous ocular surgery or trauma
- persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RayOne EMVnon-diffractive monofocal IOL | Device | Rayone EMV |
| Vivinex Impressnon-diffractive monofocal IOL | Device | Vivinex Impress XY1-EM |
Primary outcome
Visual acuity at intermediate distance
Time frame: 3 months
The visual acuity at the intermediate distance will be measured using ETDRS charts at a distance of 80 centimetres and compared between the two different IOLs. The higer the number the better outcome.
3 secondary outcomes
Visual acuity at far distance
Time frame: 3 months
Visual acuity at near distance
Time frame: 3 months
Change from baseline in the quality of life
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: Yes. De-identified participant data that underlie the results reported in this study will be available upon reasonable request for academic and non-commercial purposes beginning with results publication and ending 5 years thereafter. Proposals should be submitted to main investigator.
Related trials for Cataract
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
Aphakia, Postcataract
Not yet recruiting
Effects of Oxygen Cage Support During Cataract Surgery
Cataract
Active, not recruitingObservational study
Age-Related Eye Disease Study (AREDS) Follow-Up
Age-Related Macular Degeneration, Cataract
RecruitingObservational study
Objective Depth-of-Focus Changes During Light Adjustable Lens UV Adjustments
Light Adjustable Lens, Objective Depth of Focus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing RayOne EMV and Vivinex Impress in people with Cataract, run by Medical University of Bialystok at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joanna Konopinska, Associate proffesor (+48600471666, joannakonopinska@o2.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual acuity at intermediate distance (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.